drugset / Trial / NCT04409873

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

Phase 2 Terminated 54 enrolled University of California, San Francisco Rowpar Pharmaceuticals, Inc. · collab

RandomizedParallel-groupDouble-blindSupportive care

Summary

In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest Pro-Health Multi-Protection (Crest, USA), or Listerine Zero (Johnson and Johnson, USA). Study participants will be asked to rinse/gargle with 10-20ml (according to the rinse instructions) of the assigned solutions 4 times per day, for 30-60 seconds, for 4 weeks.

Timeline

Start: 2021-03-31
Primary completion: 2022-09-10
Completion: 2022-09-10

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cetylpyridinium	Small molecule	10 ml	Other
Subject	Cetylpyridinium	Small molecule	20 ml	Other
Subject	Essential oils without alcohol	Unknown	10 ml	Other
Subject	Essential oils without alcohol	Unknown	20 ml	Other
Subject	Hydrogen Peroxide	Small molecule	10 ml	Other
Subject	Hydrogen Peroxide	Small molecule	20 ml	Other
Subject	chlorine dioxide	Unknown	10 ml	Other
Subject	chlorine dioxide	Unknown	20 ml	Other

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

Summary

Timeline

Publications

Drugs

Indications